LLY-507: Potent SMYD2 Inhibitor for Cancer and Fibrosis Research

Executive Summary: LLY-507 is a small molecule inhibitor with <15 nM IC₅₀ for SMYD2, providing >100-fold selectivity over other methyltransferases (APExBIO). SMYD2 is overexpressed in various cancers and fibrotic diseases, correlating with poor outcomes (Chen et al. 2023). LLY-507 blocks SMYD2-mediated monomethylation of p53 at Lys370 and does not significantly alter global histone methylation. Preclinical data support its use in cell-based assays for oncology and renal fibrosis, but no in vivo or clinical data exist. The compound is provided by APExBIO for preclinical research use only.

Biological Rationale

SMYD2 (SET and MYND domain-containing protein 2) is a protein-lysine methyltransferase responsible for the monomethylation of both histone and non-histone substrates. It methylates histone H3 at lysines 4 and 36, as well as p53 at lysine 370, modulating transcription and protein function (Chen et al. 2023). SMYD2 is overexpressed in cancers such as esophageal squamous cell carcinoma, breast cancer, and hepatocellular carcinoma, and is implicated in renal fibrosis and chronic kidney disease (CKD). High SMYD2 expression correlates with poor prognosis and increased tumor proliferation (LLY-507 and the Next Frontier in SMYD2 Inhibition). Targeting SMYD2 with small molecule inhibitors like LLY-507 allows for investigation of the lysine methylation pathway in disease models where SMYD2 activity drives pathology.

Mechanism of Action of LLY-507

LLY-507 is a potent, cell-active SMYD2 inhibitor. It binds within the substrate peptide binding pocket of SMYD2, competitively blocking access to both histone and non-histone substrates. This results in inhibition of SMYD2's methyltransferase activity, with an IC₅₀ <15 nM under standard biochemical assay conditions (buffered at pH 7.5, 25°C, 30 min incubation) (LLY-507 product page). LLY-507 demonstrates >100-fold selectivity for SMYD2 compared to a panel of over 30 other methyltransferases and non-methyltransferase proteins. In cellular contexts, LLY-507 reduces monomethylation of p53 (Lys370) at submicromolar concentrations (0.1–1 μM) without affecting global H3K4 or H3K36 methylation, due to SMYD2's substrate and compartment specificity (LLY-507: Potent SMYD2 Inhibitor for Cancer and Fibrosis Research). LLY-507 does not significantly alter other histone marks in nuclei, consistent with SMYD2's predominantly cytoplasmic localization and restricted substrate profile.

Evidence & Benchmarks

• LLY-507 inhibits SMYD2 with an IC₅₀ <15 nM in enzymatic assays (25°C, buffer pH 7.5, 30 min) (APExBIO).
• Shows >100-fold selectivity for SMYD2 over 30+ other methyltransferases and unrelated proteins (Chen et al. 2023).
• Reduces SMYD2-mediated p53 Lys370 monomethylation in cultured tumor cells at 0.1–1 μM without affecting global histone methylation (sm-102.com article).
• Inhibits proliferation of liver, esophageal, and breast cancer cell lines in a dose-dependent manner (cell viability IC₅₀ typically submicromolar) (p53-tumor-suppressor-fragment.com article).
• Suppresses expression of fibrosis markers and inflammatory cytokines in renal epithelial cells exposed to cisplatin (Chen et al. 2023).
• No in vivo efficacy or clinical data reported as of June 2024 (APExBIO).

This article extends the mechanistic focus of LLY-507 and the Future of SMYD2 Inhibition: Mechanistic Insights by providing updated benchmarks and clarifying selectivity in cancer versus fibrosis models. It also updates the practical guidance in LLY-507 (SKU B6119): Practical Insights for Reliable SMYD2 Assays by integrating new evidence from recent peer-reviewed studies.

Applications, Limits & Misconceptions

LLY-507 is optimized for cell-based and cell-free assays interrogating the role of SMYD2 in lysine methylation and associated pathologies.

• Used in apoptosis assays and cancer cell proliferation inhibition studies for esophageal squamous cell carcinoma, breast, and liver cancer cells.
• Applied to investigate SMYD2's role in fibrosis and inflammatory signaling, particularly in kidney epithelial models (Chen et al. 2023).
• Tool for dissecting lysine methylation pathway modulation in oncology and fibrotic disease.
• Recommended for preclinical research only; not for in vivo or clinical trial use.

Common Pitfalls or Misconceptions

• Not a pan-methyltransferase inhibitor: LLY-507 is highly selective and does not broadly inhibit methyltransferases outside the SMYD family.
• No demonstrated in vivo efficacy: All efficacy claims are based on in vitro and cell-based data; no published animal model or clinical trial results (APExBIO).
• Water insolubility: LLY-507 is insoluble in water; use DMSO (≥57.5 mg/mL) or ethanol (≥54.7 mg/mL) for stock solutions.
• Should not be used as a direct SMYD2 knockdown substitute: Inhibition is reversible and substrate-specific, not equivalent to genetic loss-of-function.
• Does not target all p53 modifications: LLY-507 specifically blocks p53 Lys370 monomethylation by SMYD2, not other p53 post-translational modifications.

Workflow Integration & Parameters

LLY-507 (SKU B6119) is supplied as a solid compound (molecular weight 574.76, formula C₃₆H₄₂N₆O). For experimental use:

• Dissolve in DMSO (≥57.5 mg/mL) or ethanol (≥54.7 mg/mL); do not use water.
• Recommended working concentrations: 0.1–10 μM for cell-based assays; titrate according to cell type and endpoint.
• Store at −20°C, protect from light and moisture.
• Include appropriate vehicle controls; monitor cell viability and global methylation marks to confirm selectivity.
• Refer to LLY-507 product page at APExBIO for batch-specific QC and documentation.

For detailed troubleshooting and assay design, see LLY-507 (SKU B6119): Practical Insights, which provides real-world protocols and reproducibility checks.

Conclusion & Outlook

LLY-507 is a validated, potent, and selective SMYD2 inhibitor for preclinical research. Its robust selectivity profile and substrate specificity make it indispensable for dissecting lysine methylation pathway mechanisms in cancer and fibrosis models. While current data are limited to in vitro and cell-based assays, LLY-507 remains a cornerstone tool for mechanistic and translational studies. APExBIO provides quality-controlled LLY-507 for research use; in vivo studies and clinical translation remain future opportunities.